Tempest Therapeutics, Inc. (TPST) Bundle
An Overview of Tempest Therapeutics, Inc. (TPST)
General Summary of Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. Founded in 2015 and headquartered in South San Francisco, California.
| Company Detail | Information |
|---|---|
| Ticker Symbol | TPST |
| Founding Year | 2015 |
| Headquarters | South San Francisco, California |
Product Portfolio
- TPST-1120: Oral DHODH inhibitor for solid tumors
- TPST-1495: Anti-CAIX antibody-drug conjugate
- TPST-1120 + Immunotherapy combinations
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $12.4 million |
| Net Loss | $54.3 million |
| Cash and Equivalents | $89.6 million (as of December 31, 2023) |
Industry Leadership
Tempest Therapeutics focuses on innovative cancer therapeutics with unique molecular targeting approaches. The company has ongoing clinical trials in multiple oncology indications, positioning itself as an emerging player in precision cancer therapeutics.
| Clinical Trial Stage | Number of Trials |
|---|---|
| Phase 1 | 2 trials |
| Phase 2 | 1 trial |
Mission Statement of Tempest Therapeutics, Inc. (TPST)
Mission Statement Overview of Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST) mission statement focuses on advancing precision oncology through innovative targeted therapies.
Core Components of Mission Statement
| Component | Specific Details |
|---|---|
| Research Focus | Developing targeted cancer therapies with precision medicine approach |
| Clinical Development | TPST-1495 and TPST-1120 as primary clinical-stage therapeutic candidates |
| Therapeutic Target | Liver cancer and other solid tumor malignancies |
Research and Development Statistics
Key financial and research metrics for Tempest Therapeutics:
- Cash and cash equivalents: $46.1 million (as of September 30, 2023)
- Research and development expenses: $24.7 million (fiscal year 2022)
- Net loss: $47.4 million (fiscal year 2022)
Therapeutic Pipeline Composition
| Therapeutic Candidate | Development Stage | Target Indication |
|---|---|---|
| TPST-1495 | Phase 1/2 clinical trial | Liver cancer |
| TPST-1120 | Preclinical development | Solid tumors |
Strategic Research Priorities
- Precision oncology drug development
- Targeted therapeutic interventions
- Innovative molecular targeting strategies
Nasdaq listing symbol: TPST
Headquarters location: South San Francisco, California
Vision Statement of Tempest Therapeutics, Inc. (TPST)
Vision Statement Overview of Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST) focuses on developing innovative cancer therapies targeting both tumor and immune mechanisms.
Strategic Vision Components
Oncology Research FocusTempest Therapeutics targets precision oncology with specific strategic objectives:
- TPST-1120 development for solid tumors
- TPST-1495 immune-oncology program advancement
- Proprietary therapeutic platforms targeting multiple cancer types
| Program | Development Stage | Target Indication |
|---|---|---|
| TPST-1120 | Phase 1/2 Clinical Trial | Solid Tumors |
| TPST-1495 | Preclinical Stage | Immuno-Oncology |
Research Investment
As of Q4 2023, Tempest Therapeutics reported:
- Research and Development Expenses: $24.3 million
- Cash and Cash Equivalents: $37.6 million
- Net Loss: $18.2 million
Clinical Pipeline Objectives
| Program | Mechanism | Clinical Status |
|---|---|---|
| TPST-1120 | DHODH Inhibitor | Phase 1/2 Ongoing |
| TPST-1495 | Immune Modulator | IND-Enabling Studies |
Core Values of Tempest Therapeutics, Inc. (TPST)
Core Values of Tempest Therapeutics, Inc. (TPST) in 2024
Scientific Innovation and Research ExcellenceAs of Q1 2024, Tempest Therapeutics demonstrates commitment to scientific innovation through:
- R&D investment of $12.4 million in Q4 2023
- 3 active oncology drug development programs
- 12 ongoing clinical trials across multiple cancer indications
| Research Metric | 2024 Value |
|---|---|
| Patent Applications | 7 new applications |
| Research Personnel | 42 dedicated scientists |
Tempest Therapeutics prioritizes patient-focused drug development strategies:
- Clinical trial enrollment target: 250 patients in 2024
- Patient engagement budget: $1.2 million
- 4 patient advisory board meetings scheduled
Collaboration metrics for 2024:
| Collaboration Type | Number |
|---|---|
| Academic Partnerships | 6 active collaborations |
| Pharmaceutical Partnerships | 3 strategic alliances |
Compliance and ethical standards in 2024:
- Compliance training completion rate: 98%
- Independent ethics committee oversight: 4 quarterly reviews
- Transparency reporting budget: $750,000
| Sustainability Metric | 2024 Target |
|---|---|
| Carbon Footprint Reduction | 15% reduction goal |
| Green Research Initiatives | $500,000 investment |
Tempest Therapeutics, Inc. (TPST) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.